Ceruglan - instructions for use, doses, side effects, contraindications

Composition:1 ampoule (2 ml solution) contains 10 mg of metoclopramide hydrochloride as the active substance.
Excipients: sodium sulfite anhydrous, sodium chloride, Trilon B, water for injection.

Description:A clear, colorless or slightly colored solution, odorless or almost odorless.

Pharmacotherapeutic group:Antiemetic means - dopamine receptors central antagonist.

ATX: & nbsp

A.03.F.A Motility stimulators GIT

A.03.F.A.01 Metoclopramide

Pharmacodynamics:Metoclopramide is a specific blocker of dopamine (D2) and serotonin receptors. Has antiemetic effect due to influence on the chemoreceptors of the trigger zone of the medulla oblongata.
The drug has a regulating and normalizing effect on the activity of the gastrointestinal tract. Reduces the motor activity of the esophagus, increases the tone of the lower sphincter of the esophagus, accelerates the emptying of the stomach, and accelerates the movement of food through the small intestine, without causing diarrhea.
Stimulates the secretion of prolactin.
Metoclopramide passes through the placental and blood-brain barrier and penetrates into the mother's milk.

Indications:Vomiting, nausea of different genesis (in some cases it can be effective for nausea and vomiting caused by the use of cytostatics). Atony and hypotension of the stomach and intestines (in particular, postoperative); biliary dyskinesia; reflux esophagitis; functional stenosis of the pylorus. It is used to enhance peristalsis during radiocontrast studies of the gastrointestinal tract, and also as a means to facilitate duodenal sounding.

Contraindications:Bleeding from the gastrointestinal tract, pyloric stenosis, mechanical intestinal obstruction, perforation of the stomach or intestine, pheochromocytoma, extrapyramidal disorders, epilepsy, prolactin-dependent tumors, pregnancy,children under 2 years of age, individual intolerance metoclopmide and other components of the drug.

Carefully:Caution should be used in patients with hypertension, Parkinson's disease with impaired liver and kidney function, elderly patients and children, because they have much higher risk of dyskinetic syndrome.

Pregnancy and lactation:We do not recommend the use of Tseruglana® during lactation should decide the issue of termination of breastfeeding, if necessary, use of the drug.
During pregnancy (2 and 3 trimesters) and children aged 2 to 14 years, the drug is prescribed for life indications.

Dosing and Administration:The solution Cerulgan® is administered intramuscularly and intravenously. Adults appoint 10 mg 3-4 times a day. The maximum single dose is 20 mg; daily - 60 mg. For children of 14 years old can vary from 2 single dose of 0.1 mg / kg of body weight, the highest daily dose - 0.5 mg / kg body weight. The frequency of administration is 1 -3 times a day.
The duration of treatment is determined by the doctor and is usually 4-6 weeks. In some cases, treatment can be continued up to 6 months.
In case of renal insufficiency the dose of the drug should be reduced (with creatinine clearance up to 10 ml / min - 10 microns once a day, from 11 to 60 ml / min - 15 mg per day, divided into two injections).
Prevention and treatment of nausea and vomiting caused by the use of cytostatics. Depending on the nature of the chemotherapeutic treatment, the daily dose is from 1 to 4 mg / kg of body weight of the patient.
Injection solution Cerulgan® can be diluted with an isotonic solution of sodium chloride or 5% glucose solution.

Side effects:At the beginning of treatment, constipation, diarrhea, dry mouth, fatigue, drowsiness, headache, dizziness, depression, irritation, irritability, fear, anxiety, allergic reactions are possible. In some cases, mainly in children, a dyskinetic syndrome may develop. With prolonged use in elderly patients, it is possible to develop the phenomena of parkinsonism, tardive dyskinesia. In rare cases with long-term use of the drug in high doses - methemoglobinemia, edema, galactorrhea, gynecomastia, menstrual irregularities.

Overdose:There may be hypersomnia, disorientation and extrapyramidal disorders. As a rule, the symptomatology disappears after stopping the drug within 24 hours.
When necessary, treatment with holinoblokatorami and antiparksonic drugs.

Interaction:Action Cerulgan ® can weaken the anticholinesterase drugs. The drug enhances the absorption of tetracycline, ampicillin, paracetamol, acetylsalicylic acid, le-water drops; reduces the absorption of digoxin and cimetidine. Strengthens the effect of alcohol and drugs, depressing the central nervous system. You should not prescribe simultaneously with neuroleptics, tk. increased risk of extrapyramidal reactions.

Special instructions:During the treatment with the drug is not recommended the use of alcohol.

Effect on the ability to drive transp. cf. and fur:When using the drug should be avoided potentially dangerous activities that require increased attention, rapid mental and motor reaction (driving vehicles, etc.).

Form release / dosage:2 ml in ampoules.

Storage conditions:List B. Keep in a place out of the reach of children.

Shelf life:5 years.
Do not use later than the time specified in the etiquette

Terms of leave from pharmacies:On prescription

Registration number:P N001576 / 01-2002

Date of registration:14.08.2008

Expiration Date:Unlimited

The owner of the registration certificate:BRYNTSALOV-A, CJSC BRYNTSALOV-A, CJSC Russia

Manufacturer: & nbsp

BRYNTSALOV-A, CJSC Russia

Information update date: & nbsp2016-09-11

Illustrated instructions

Instructions

Cerulgan® (Ceruglan)